千金药业：子公司千金湘江药业获得铝碳酸镁咀嚼片药品注册证书

Core Viewpoint - Qianjin Pharmaceutical's subsidiary, Qianjin Xiangjiang Pharmaceutical, has received approval from the National Medical Products Administration for the registration of aluminum magnesium carbonate chewable tablets, enhancing the company's product pipeline and supporting sustainable development [1] Group 1 - The approved drug is a first-line medication for the digestive system, providing antacid, bile acid neutralization, and mucosal protection effects [1] - The approval of the drug registration certificate is equivalent to passing the consistency evaluation, which is a significant milestone for the company [1] Group 2 - The production and sales of the drug are subject to national policies and market environment changes, indicating a high level of uncertainty [1]